Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.58) per share for the year. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.36.
A number of other equities analysts have also weighed in on ZNTL. UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. Finally, Wedbush reissued a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $8.24.
Check Out Our Latest Research Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Price Performance
ZNTL traded down $0.06 during trading on Friday, hitting $1.63. The company's stock had a trading volume of 1,745,317 shares, compared to its average volume of 2,825,820. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $18.07. The stock has a market cap of $115.81 million, a PE ratio of -0.65 and a beta of 1.86. The firm's 50 day moving average price is $2.90 and its 200-day moving average price is $3.24.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ZNTL. China Universal Asset Management Co. Ltd. grew its position in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock valued at $50,000 after buying an additional 5,333 shares during the last quarter. Carson Advisory Inc. grew its holdings in shares of Zentalis Pharmaceuticals by 55.8% during the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock valued at $90,000 after purchasing an additional 8,800 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals in the third quarter worth $37,000. Paloma Partners Management Co bought a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000. Finally, 49 Wealth Management LLC boosted its stake in Zentalis Pharmaceuticals by 81.7% during the 3rd quarter. 49 Wealth Management LLC now owns 22,558 shares of the company's stock valued at $83,000 after purchasing an additional 10,145 shares during the period.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Stories
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
